Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Debt: 2012-2024

Historic Non-Current Debt for Ptc Therapeutics (PTCT) over the last 11 years, with Dec 2024 value amounting to $285.4 million.

  • Ptc Therapeutics' Non-Current Debt rose 0.42% to $286.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $286.0 million, marking a year-over-year increase of 0.42%. This contributed to the annual value of $285.4 million for FY2024, which is 0.42% up from last year.
  • Ptc Therapeutics' Non-Current Debt amounted to $285.4 million in FY2024, which was up 0.42% from $284.2 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Non-Current Debt registered a high of $571.7 million during FY2022, and its lowest value of $281.9 million during FY2021.
  • Its 3-year average for Non-Current Debt is $380.4 million, with a median of $285.4 million in 2024.
  • As far as peak fluctuations go, Ptc Therapeutics' Non-Current Debt surged by 102.81% in 2022, and later slumped by 50.29% in 2023.
  • Ptc Therapeutics' Non-Current Debt (Yearly) stood at $309.1 million in 2020, then declined by 8.81% to $281.9 million in 2021, then soared by 102.81% to $571.7 million in 2022, then slumped by 50.29% to $284.2 million in 2023, then rose by 0.42% to $285.4 million in 2024.